| Literature DB >> 2497646 |
Abstract
Norplant offers long-term contraception through the use of subdermal capsules filled with levonorgestrel. The six capsules are implanted in the inside part of the upper arm. The levonorgestrel is released from the capsules gradually, providing contraception for about 5 years. The primary mechanism of action of Norplant is suppression of ovulation. Studies have shown a pregnancy rate of 0.6/100 woman-years after 1 year and a cumulative rate of 1.5/100 woman-years at 5 years. Principal side effects are irregular menstrual bleeding and headaches. No changes in carbohydrate metabolism, blood coagulation, or liver function have been reported. Lipid levels have decreased 5% to 15%. After removal of Norplant, fertility returns rapidly, and there have been no adverse effects on infants. Norplant is currently approved in 12 countries; clinical trials are being conducted in 37 countries.Entities:
Keywords: Contraception; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--side effects; Contraceptive Effectiveness; Contraceptive Implants; Contraceptive Methods; Demographic Factors; Evaluation; Family Planning; Fertility; Fertility Measurements; Levonorgestrel--side effects; Literature Review; Population; Population Dynamics; Pregnancy Rate; Qualitative Evaluation; Use-effectiveness
Mesh:
Substances:
Year: 1989 PMID: 2497646 DOI: 10.1016/s0002-9378(89)80014-6
Source DB: PubMed Journal: Am J Obstet Gynecol ISSN: 0002-9378 Impact factor: 8.661